<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>immune-mediated | Nano Publications</title>
	<atom:link href="https://bibliography.nanobiotix.com/fr/tag/immune-mediated-fr/feed/" rel="self" type="application/rss+xml" />
	<link>https://bibliography.nanobiotix.com/fr/</link>
	<description>Navigate through all Nanobiotix publications online</description>
	<lastBuildDate>Thu, 26 May 2022 15:15:40 +0000</lastBuildDate>
	<language>fr-FR</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.0.3</generator>

<image>
	<url>https://bibliography.nanobiotix.com/wp-content/uploads/2019/11/cropped-n-icon-512x512-32x32.png</url>
	<title>immune-mediated | Nano Publications</title>
	<link>https://bibliography.nanobiotix.com/fr/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model</title>
		<link>https://bibliography.nanobiotix.com/fr/2020-nbtxr3-nanoparticle-with-immunoradiation-improves-survival-and-generates-long-term-anti-tumor-memory-in-an-anti-pd1-resistant-murine-lung-cancer-model/</link>
		
		<dc:creator><![CDATA[nano-pub]]></dc:creator>
		<pubDate>Thu, 26 May 2022 14:50:27 +0000</pubDate>
				<category><![CDATA[Abstracts]]></category>
		<category><![CDATA[In Vitro in Vivo NBTXR3]]></category>
		<category><![CDATA[In Vivo]]></category>
		<category><![CDATA[Anti-PD-1]]></category>
		<category><![CDATA[high-dose]]></category>
		<category><![CDATA[immune-mediated]]></category>
		<category><![CDATA[NBTXR3]]></category>
		<category><![CDATA[Tumor]]></category>
		<guid isPermaLink="false">https://bibliography.nanobiotix.com/?p=2744</guid>

					<description><![CDATA[<p>Although treatment with high-dose (HD) radiation (XRT) and NBTXR3 on primary tumors in combination with systemic anti-PD1 was able to significantly improve abscopal effect in 344SQR murine metastatic lung cancer model, most of the mice eventually died due to the growth of secondary tumors. […]</p>
The post <a href="https://bibliography.nanobiotix.com/fr/2020-nbtxr3-nanoparticle-with-immunoradiation-improves-survival-and-generates-long-term-anti-tumor-memory-in-an-anti-pd1-resistant-murine-lung-cancer-model/">2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model</a> first appeared on <a href="https://bibliography.nanobiotix.com/fr/">Nano Publications</a>.]]></description>
										<content:encoded><![CDATA[<div class="az-main-section-content az-module az-padding-top-0 az-padding-bottom-0 az-section-default az-section-with-equal no-animate-content az-module-bg-color">
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg" style="background: #28282e;"></div>
            
        </div><div class="container-fluid az-container-no-padding"><div class="row row-parent az-gutter-0 az-equal"><div class="single-clms col-md-12 az-main-col-content az-module az-v-space-clm no-animate-content az-module-default"><div class="az-col az-clm-padding-0" ><div class="az-col-cont"><div class="row row-inner az-padding-top-0 az-padding-bottom-0 az-gutter-0 az-equal no-animate-content"><div data-animation-type="ani-in" data-animation-in="fadeInUp" data-animation-out="none" data-animation-speed="default" data-animation-delay="200" data-offset-down="90" data-offset-up="none" class="single-clms col-md-6 az-main-col-content az-module az-col-pos-middle az-v-space-clm animate-content az-module-bg-image"><div class="az-col az-clm-padding-105" data-col-min-height-default="700" data-col-min-height-sm="400" data-col-min-height-xs="350" style="min-height: 700px;">
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg  az-imagesLoadedBg" style="background-image: url(https://bibliography.nanobiotix.com/wp-content/uploads/2017/02/Working-it.jpg); background-position: center center; background-repeat: no-repeat; background-size: cover;">
            
    <div class="az-module-mask-group">
        <span class="az-module-mask-bg is-bg main-mask"></span>
        
    </div>
            </div>
            
        </div><div class="az-col-cont"><div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div>
<div class="az-content-element-wrapper az-box-icon-wrapper az-margin-top-0 az-margin-bottom-0 no-animate-content">
    <div class="az-box-icon az-box-icon-top">
            <div class="az-icon-container" style="color: #ffffff; font-size: 50px;"><i class="fa fa-edit"></i>
            </div><div class="az-box-icon-content az-font-custom az-font-color-custom" style="color: #ffffff;"><h3 class="az-box-icon-title">Authors</h3><p>Yun Hu<span class="notes up">1</span>, James Welsh<span class="notes up">2</span>, Sebastien Paris<span class="notes up">1</span>, Hampartsoum Barsoumian<span class="notes up">1</span>, Chike Abana<span class="notes up">1</span>, Saumil Gandhi<span class="notes up">1</span>, Quynh Nguyen<span class="notes up">1</span>, Maria Cortez<br />
<span class="notes"><br />
1 — MD Anderson Cancer Center, Houston, TX, USA<br />
2 — Nanobiotix, Paris, France<br />
</span></p>
</div></div>
</div>
<div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div></div></div></div><div data-animation-type="ani-in" data-animation-in="fadeInUp" data-animation-out="none" data-animation-speed="default" data-animation-delay="300" data-offset-down="90" data-offset-up="none" class="single-clms col-md-6 az-main-col-content az-module az-col-pos-middle az-v-space-clm animate-content az-module-bg-color"><div class="az-col az-clm-padding-105" >
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg" style="background: #ffffff;"></div>
            
        </div><div class="az-col-cont"><div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div>
<div class="az-content-element-wrapper az-box-icon-wrapper az-margin-top-0 az-margin-bottom-0 no-animate-content">
    <div class="az-box-icon az-box-icon-top">
            <div class="az-icon-container" style="color: #28282e; font-size: 50px;"><i class="az-icon az-icon-layers2"></i>
            </div><div class="az-box-icon-content"><h3 class="az-box-icon-title">Summary</h3><p><b>Background:</b> Although treatment with high-dose (HD) radiation (XRT) and NBTXR3 on primary tumors in combination with systemic anti-PD1 was able to significantly improve abscopal effect in 344SQR murine metastatic lung cancer model, most of the mice eventually died due to the growth of secondary tumors. Therefore, we intended to use HD-XRT plus NBTXR3 injection into primary tumors and low-dose (LD) radiation on secondary tumors plus dual-agent immunotherapy (IT) of anti-PD1 and anti-CTLA-4 to acheive complete control of both the primary and secondary tumors in mice.</p>
<p><b>Methods:</b> Five groups of 8 mice each were inoculated subcutaneously with 5 × 104 anti-PD1-resistant 344SQR cells in each hind leg, 3 days apart, to establish ‘primary’ (right) and ‘secondary’ (left) tumors. All mice in treatment groups received intraperitoneal anti-PD1 and anti-CTLA-4 on days 4, 7, 10, and 13, and continuing anti-PD1 treatment on days 20, 27, 34, 41, and 49 and 12Gy x3 (HD-XRT) to the primary tumors on days 7, 8 and 9. Primary tumors in groups 3 and 5 also received intratumoral NBTXR3 on day 6. Secondary tumors in groups 4 and 5 were also irradiated with 1Gyx2 (LD-XRT) on days 12 and 13. Experimental groups were designated as 1=Control, 2=HD+IT, 3=NBTXR3+HD+IT, 4=HD+LD+IT, and 5=NBTXR3+HD+LD+IT. The secondary tumors were analyzed by flow cytometry and Nanostring. On day 178, the survivor mice were rechallenged with 5 × 104 344SQR cells on the right flank and the tumor growth was monitored for an additional 36 days.</p>
<p><b>Results:</b> All mice in all the groups except NBTXR3+HD+LD+IT died due to the growth of either the primary tumor or the secondary tumor by day 36. Both the primary and the secondary tumors in 4 mice of NBTXR3+HD+LD+IT group were completely eliminated. No tumor growth was observed in these mice after rechallenged with 344SQR cells. Flow cytometry data demonstrated that only the mice in the groups with NBTXR3 had significantly more CD8+ T cell infiltration in the secondary tumor collected on day 16 than the control. Both flow cytometry and Nanostring data showed that only the mice in NBTXR3+HD+LD+IT had a significantly higher CD8+ Tcell/Treg cell ratio than the control.</p>
<p><b>Conclusions:</b> The combination of NBTXR3 plus high and low dose radiation with immunotherapy effectively controlled the growth of both primary and secondary tumors, significantly extended the survival, generating long-term antitumor memory. This combination therapy induced immune-mediated control of the secondary tumor at both genetic and cellular levels.</p>
</div></div>
</div>
<div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div></div></div></div></div></div></div></div></div></div></div>The post <a href="https://bibliography.nanobiotix.com/fr/2020-nbtxr3-nanoparticle-with-immunoradiation-improves-survival-and-generates-long-term-anti-tumor-memory-in-an-anti-pd1-resistant-murine-lung-cancer-model/">2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model</a> first appeared on <a href="https://bibliography.nanobiotix.com/fr/">Nano Publications</a>.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
